Form 4: Moderna Director Noubar Afeyan Sells Shares Under 10b5-1 Trading Plan

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on May 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 29, 2024, Noubar Afeyan, a director of Moderna, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on February 27, 2023, and amended on November 7, 2023.
• A total of 22,000 shares were sold in multiple transactions at varying prices.
• The prices ranged from $140.34 to $148.50 per share.
• Following the reported transactions, Afeyan directly owns 1,961,931 shares of Moderna.
• Afeyan also has indirect ownership through Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, reporting the sale of shares by a company director. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Sales by insiders are a common occurrence and are often planned in advance, especially through Rule 10b5-1 trading plans. These plans allow insiders to sell shares at predetermined times and prices, avoiding accusations of trading on non-public information.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, although the existence of a pre-arranged trading plan mitigates this concern.

Key Dates